Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Melanoma
Conditions
Metastatic Melanoma
Trial Timeline
Jan 28, 2019 → Mar 4, 2022
NCT ID
NCT03817125About Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401
Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401 is a phase 1 stage product being developed by Seres Therapeutics for Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03817125. Target conditions include Metastatic Melanoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03817125 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Melanoma